Patents by Inventor Efthimios Koutris

Efthimios Koutris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preservative free pharmaceutical compositions for ophthalmic administration
    Patent number: 10772830
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 15, 2020
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Preservative free pharmaceutical compositions for ophthalmic administration
    Patent number: 10702471
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: July 7, 2020
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Preservative free pharmaceutical compositions for ophthalmic administration
    Patent number: 10350161
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 16, 2019
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Pharmaceutical composition containing phosphate binding polymer
    Patent number: 9849147
    Abstract: The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake. A process for the preparation thereof is disclosed.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 26, 2017
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Analia Diakidou, Georgia Papanikolaou, Panagiotis Mparmpalexis
  • Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
    Patent number: 9675551
    Abstract: The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: June 13, 2017
    Assignee: EXPERMED S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vicky Samara, Amalia Diakidou, Aggelos Karatzas
  • Method for improving the bioavailability of low aqueous solubility drugs
    Patent number: 9561186
    Abstract: The present invention relates to the implementation of a new method for manufacturing solid dosage forms for oral administration comprising poorly water soluble active ingredients which overcomes the associated solubility problems and affords improved dissolution profile.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: February 7, 2017
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Amalia Diakidou, Georgia Papanikolaou
  • NOVEL METHOD FOR IMPROVING THE BIOAVAILABILITY OF LOW AQUEOUS SOLUBILITY DRUGS
    Publication number: 20150290137
    Abstract: The present invention relates to the implementation of a new method for manufacturing solid dosage forms for oral administration comprising poorly water soluble active ingredients which overcomes the associated solubility problems and affords improved dissolution profile.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 15, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Amalia Diakidou, Georgia Papanikolaou
  • PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20150231080
    Abstract: The present invention relates to a solid dosage form for oral administration comprising a therapeutically effective amount of an atypical antipsychotic agent or a pharmaceutically acceptable salt, in particular Quetiapine, incorporated in a matrix formed by non-gelling polymers. It also relates to a process for the preparation thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: August 20, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasilika Samara, Amalia Diakidou, Georgia Papanikolaou, Panagiotis Barmpalexis
  • PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHATE BINDING POLYMER
    Publication number: 20150182555
    Abstract: The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake. A process for the preparation thereof is disclosed.
    Type: Application
    Filed: June 15, 2012
    Publication date: July 2, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Analia Diakidou, Georgia Papanikolaou, Panagiotis Mparmpalexis
  • STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20150165045
    Abstract: The present invention relates to a controlled release sterile injectable formulation in the form of solution, suspension or sol-gel formulation for intramuscular or subcutaneous administration comprising a therapeutically effective amount of a neurokinin 1 receptor antagonist, in particular Aprepitant or Fosaprepitant or pharmaceutical acceptable salt, derivative or metabolite thereof. It also relates to a process for developing such formulations.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 18, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Sotiria Chatidou, Amalia Diakidou, Panagiotis Barmpalexis, Louiza Konstanti, Katerina Minioti
  • OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20150080385
    Abstract: The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: March 8, 2013
    Publication date: March 19, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Efstathia Milouli, Ioanna Kontiza, Ioanna Koutri
  • Pharmaceutical formulation containing an HMG-COA reductase inhibitor and method for the preparation thereof
    Patent number: 8835486
    Abstract: An improved pharmaceutical formulation for oral administration includes a therapeutically effective quantity of an active ingredient and a stabilizer. The active ingredient is Fluvastatin, or pharmaceutically acceptable salts thereof, and the stabilizer is a mixture of Carrageenans. The stabilizer inhibits isomerization, and/or elimination, and/or oxidation and/or recrystallization of the active ingredient.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: September 16, 2014
    Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris
  • SUBLINGUAL PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIHISTAMINE AGENT AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20140235656
    Abstract: The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 21, 2014
    Applicant: EXPERMED S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vicky Samara, Amalia Diakidou, Aggelos Karatzas
  • Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
    Patent number: 8187635
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: May 29, 2012
    Assignee: Pharmathen S.A
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Ioanna Koutri, Eleni Stathaki
  • Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
    Publication number: 20110065751
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation.
    Type: Application
    Filed: October 16, 2007
    Publication date: March 17, 2011
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Anastasia Kalaskani, Eleni Stathaki
  • Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
    Publication number: 20110033538
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
    Type: Application
    Filed: October 16, 2007
    Publication date: February 10, 2011
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Ioanna Koutri, Eleni Stathaki
  • SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20100297225
    Abstract: The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof.
    Type: Application
    Filed: December 20, 2007
    Publication date: November 25, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Ioanna Koutri, Vicky Samara, Dimitrios Bikiaris
  • Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof
    Publication number: 20100196469
    Abstract: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression.
    Type: Application
    Filed: June 25, 2007
    Publication date: August 5, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Elli Ioannidou, Vicky Samara, Dimitrios Bikiaris
  • PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20100137400
    Abstract: The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof.
    Type: Application
    Filed: May 12, 2006
    Publication date: June 3, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris